Denali Therapeutics Inc. Common Stock (DNLI)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.59 (+6.82%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Denali Therapeutics Inc. Common Stock (DNLI)
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Key Insights

Critical company metrics and information
  • Share Price

    $24.89
  • Market Cap

    $3.58 Billion
  • Total Outstanding Shares

    143.92 Million Shares
  • Total Employees

    390
  • Dividend

    No dividend
  • IPO Date

    December 8, 2017
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.denalitherapeutics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$-57.38 Million
Net Cash Flow From Financing Activities$493.18 Million
Net Cash Flow From Operating Activities$-362.64 Million
Net Cash Flow From Financing Activities, Continuing$493.18 Million
Net Cash Flow From Investing Activities, Continuing$-187.92 Million
Net Cash Flow From Investing Activities$-187.92 Million
Net Cash Flow From Operating Activities, Continuing$-362.64 Million
Net Cash Flow, Continuing$-57.38 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Benefits Costs and Expenses$322.56 Million
Net Income/Loss Attributable To Parent$-427.49 Million
Income/Loss From Continuing Operations Before Tax$-308.02 Million
Revenues$14.54 Million
Income/Loss From Continuing Operations After Tax$-427.49 Million
Basic Average Shares$162.88 Million
Basic Earnings Per Share$2.76
Research and Development$404.46 Million
Costs And Expenses$504.60 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Other Operating Expenses$100.15 Million
Diluted Earnings Per Share$2.76
Net Income/Loss$-427.49 Million
Diluted Average Shares$162.88 Million
Operating Expenses$504.60 Million
Net Income/Loss Available To Common Stockholders, Basic$-427.49 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Operating Income/Loss$-490.07 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities And Equity$1.45 Billion
Fixed Assets$50.82 Million
Other Non-current Assets$534.35 Million
Liabilities$135.52 Million
Equity Attributable To Parent$1.32 Billion
Noncurrent Liabilities$48.42 Million
Equity$1.32 Billion
Wages$14.87 Million
Assets$1.45 Billion
Equity Attributable To Noncontrolling Interest$0.00
Other Current Liabilities$62.63 Million
Noncurrent Assets$585.17 Million
Current Assets$868.84 Million
Accounts Payable$9.59 Million
Current Liabilities$87.09 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.